Oncolytics Biotech Inc

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of oncology treatments. Its lead asset is pelareorep, an intravenously delivered immunotherapeutic agent being developed for gastrointestinal tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. The company has an agreement with Roche Holding AG for the supply of the immune checkpoint inhibitor atezolizumab for use in its sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.